Background: CD45RO is an isoform of CD45, a protein tyrosine phosphatase that regulates T cell receptor and B cell receptor signaling pathways. CD45RO is the shortest of the eight isoforms and is expressed on activated and memory T cells and is absent from naive T cells, making CD45RO a useful marker for differentiating T cell subsets. CD45RO is also expressed on B cell subsets, activated monocytes and macrophages. CD45RO may have prognostic value in certain cancers, including non-small cell lung cancer.

Validation: Each lot of conjugated CD45RO antibody is quality control tested by MIBIscope™ analysis of stained tissue microarrays using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of CD45RO antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Paulsen, E.E., Kilvaer, T., Khanehkenari, M.R., Maurseth, R.J., Al-Saad, S., Hald, S.M., Al-Shibli, K., Andersen, S., Richardsen, E., Busund, L.T., Bremnes, R., Donnem, T. CD45RO(+) Memory T Lymphocytes–a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. Neoplasia. 2015;17(11):839-48.

* Conjugate tested on human tissue.